869 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by US Bancorp DE

US Bancorp DE acquired a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 869 shares of the company’s stock, valued at approximately $44,000.

Several other large investors have also recently added to or reduced their stakes in MLTX. California State Teachers Retirement System lifted its position in MoonLake Immunotherapeutics by 2.7% in the 1st quarter. California State Teachers Retirement System now owns 16,366 shares of the company’s stock valued at $822,000 after purchasing an additional 429 shares during the last quarter. DNB Asset Management AS grew its position in MoonLake Immunotherapeutics by 29.8% in the 2nd quarter. DNB Asset Management AS now owns 7,372 shares of the company’s stock worth $324,000 after purchasing an additional 1,694 shares during the last quarter. Quarry LP increased its stake in shares of MoonLake Immunotherapeutics by 172.7% in the second quarter. Quarry LP now owns 3,000 shares of the company’s stock valued at $132,000 after purchasing an additional 1,900 shares during the period. Handelsbanken Fonder AB raised its holdings in shares of MoonLake Immunotherapeutics by 26.2% during the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after buying an additional 2,700 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its position in shares of MoonLake Immunotherapeutics by 5.7% during the first quarter. Affinity Asset Advisors LLC now owns 75,000 shares of the company’s stock worth $3,767,000 after buying an additional 4,012 shares during the period. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX opened at $48.83 on Monday. The firm’s 50 day moving average is $49.87 and its 200-day moving average is $45.75. MoonLake Immunotherapeutics has a 12-month low of $37.55 and a 12-month high of $64.98. The stock has a market capitalization of $3.12 billion, a P/E ratio of -37.85 and a beta of 1.28.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same quarter last year, the firm earned ($0.18) earnings per share. As a group, equities research analysts forecast that MoonLake Immunotherapeutics will post -1.74 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Simon Sturge sold 171,000 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $53.72, for a total value of $9,186,120.00. Following the completion of the sale, the director now owns 171,980 shares in the company, valued at approximately $9,238,765.60. This represents a 49.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.02% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $62.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Wedbush reissued an “outperform” rating and set a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research note on Monday, September 23rd. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday. Finally, Wolfe Research downgraded shares of MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a research report on Monday, August 26th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $79.00.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.